BioLineRx Ltd. (NASDAQ:BLRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
Other equities research analysts have also recently issued research reports about the company. S&P Equity Research dropped their price target on BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. Roth Capital restated a “buy” rating and issued a $7.00 price target on shares of BioLineRx in a research note on Monday, September 26th. Finally, Maxim Group restated a “hold” rating and issued a $1.00 price target on shares of BioLineRx in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) opened at 1.07 on Tuesday. The firm’s market cap is $60.37 million. BioLineRx has a 52 week low of $0.71 and a 52 week high of $1.73. The stock has a 50 day moving average of $1.02 and a 200 day moving average of $0.93.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.02. Analysts anticipate that BioLineRx will post ($0.26) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in BioLineRx stock. Menta Capital LLC boosted its stake in BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned 0.18% of BioLineRx worth $101,000 at the end of the most recent quarter. 12.46% of the stock is owned by institutional investors and hedge funds.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.